Cardiovascular outcomes of semaglutide and tirzepatide for patients with type 2 diabetes in clinical practice

Cardiovascular outcome trials of the incretin-based medicines tirzepatide and semaglutide have shown benefits in populations with varying levels of cardiovascular risk. However, without direct head-to-head comparisons, treatment decisions rely on…